| Abstract |
Objective: To explore the effect of liraglutide on the clinical efficacy of patients with mild cognitive impairment in metabolic syndrome. Methods: From December 2018 to December 2019, 96 patients with metabolic syndrome were selected as subjects, and the patients were randomly selected and divided into 2 groups. The control group was treated with conventional aspart insulin and the test group was treated with liraru peptide therapy. The patients cognitive dysfunction scores were evaluated, and the incidence of adverse reactions and total clinical efficacy were evaluated. Results: The difference between the MoCA score and the MMSE score before treatment in the two groups was small, and the difference was not statistically significant (P>0.05). The MoCA score and MMSE score in the experimental group were increased compared with those in the control group after treatment, and the difference was statistically significant. (P<0.05). One case of nausea, one case of diarrhea, and one case of fatigue were found during the treatment of the test group; one case of nausea, two cases of vomiting, three cases of diarrhea, five cases of asthenia, and three cases of headache were found during the treatment of the control group; The rate of 6.25% decreased compared with 29.17% in the control group, and the difference was statistically significant (P<0.05). In the evaluation of the experimental group, 16 cases were basically cured, 24 cases were improved, and the control group was 12 cases were basically cured, and 19 cases were improved. The total effective rate of clinical efficacy in the experimental group was 83.33%, which was larger than the total effective rate of clinical efficacy in the control group, 64.58%. The amplitude increased, and the difference was statistically significant (P<0.05). Conclusion: The liraglutide treatment scheme can effectively improve the mild cognitive dysfunction in patients with metabolic syndrome, and the treatment process is safe and the clinical effect is good, which is suitable for clinical popularization and application.
|